CNS biotech's stock dives — again — as lead candidate fails second PhIII test
On Wednesday, Relmada Therapeutics ran into yet another major problem for its lead candidate, two months after facing an earlier setback.
The CNS-focused biotech revealed that REL-1017, its lead candidate that it has been developing for major depressive disorder, failed to reach the primary endpoint in a Phase III study, looking at the drug as an adjunctive treatment. The endpoint was a statistically significant improvement in depression symptoms compared to placebo at 28 days, measured by the Montgomery-Asberg Depression Rating Scale.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.